India Markets open in 3 hrs 39 mins

Medtronic plc (MDT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
117.86+0.89 (+0.76%)
At close: 4:00PM EST

118.00 +0.14 (0.12%)
After hours: 6:40PM EST

Sign in to post a message.
  • [
    From Seeking Alpha just now

    Medtronic (NYSE:MDT): Q3 Non-GAAP EPS of $1.29 beats by $0.14; GAAP EPS of $0.94 beats by $0.22.
  • J
    From 02/17
    Morgan Stanley Expects Medtronic, Inc. (MDT) To Miss Consenus Revenue

    a day ago

    He stated "Based on peer results and management commentary, we expect Medtronic to miss Cns revenues by ~50-250 bps given December-to-January resurgence (i.e., we expect a ~flat to -2% organic quarter), still positioning Medtronic toward the high-end of C4Q Device averages (see Exhibit 2 for peer 2-year stack analysis). Absolute results matter less, while evidence that Medtronic may be weathering resurgence better than peers matters more. We remain comfortable with the risk/reward into the quarter and continue to favor Medtronic as one of the best names in our coverage to play 2021 Device recovery."
  • B
    Does anyone have a solid argument as to whether MDT could be held liable (meaning a lawsuit) for the recalled stents? Thoughts?
  • G
    Posted two hours ago, the big money is betting on MDT:

    Cambiar Investors LLC grew its holdings in Medtronic plc (NYSE:MDT) by 18.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,910 shares of the medical technology company’s stock after purchasing an additional 60,210 shares during the period. Medtronic comprises about 1.8% of Cambiar Investors LLC’s investment portfolio, making the stock its 20th biggest holding. Cambiar Investors LLC’s holdings in Medtronic were worth $45,674,000 at the end of the most recent quarter.

    Several other hedge funds have also bought and sold shares of MDT. Diversified LLC bought a new position in Medtronic during the fourth quarter valued at approximately $25,000. Spectrum Management Group LLC boosted its position in Medtronic by 317.5% in the third quarter. Spectrum Management Group LLC now owns 263 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 200 shares during the last quarter. Clark Financial Advisors purchased a new stake in shares of Medtronic during the 4th quarter valued at about $29,000. Crewe Advisors LLC purchased a new stake in shares of Medtronic during the 3rd quarter valued at about $31,000. Finally, Catalyst Private Wealth LLC bought a new position in shares of Medtronic in the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 79.17% of the company’s stock
  • M
    Medtronic is backing the SPAC started by Intel chairman Omar Ishrak in the health technology sector. Its also setup with co-chief exec officers Jean Nehme who helped found AI startup Digital Surgery Ltd and then sold it to Medtronic & Joshua Fink who runs the investment firm Ophir Holdings LLC and is the son of BlackRock Inc.’s Larry Fink. I read about Digital Surgery wins ago and totally missed the boat on buying in before but bought into the SPAC since it just launched closer to the NAV. Looks interesting if anyone else wants to read up on it.
  • B
    Bill mddb
    Nice Friday lift of $1.02 on no news. Below av volume indicates a dearth of sellers. Hopefully, MDT will meet or beat the av analyst estimate of 80 basis points of revenue growth compared to last year's Q3. The analysts also project adjusted operating EPS for FY 2021 of $4.20 and for next year, FY 2022, the analyst estimate is $5.83 or about a 40% pop due to comparison back to C-19 depressed quarters and the dip to $4.20 Op EPS. Since FY 2022 starts May 1, 2021, it should encourage a current bid for the stock based on 12 month forward projections of Op EPS. The next question is what will FY 23 look like beginning May 1, 2022 -- that's really "next year" for MDT. I'm looking forward to the earnings call coming up in about 10 days. The stock trading at 52 week highs is a good sign the market is optimistic.
  • O
    one of the best stocks to own.
    diversified portfolio of medical devices products in need globally.
    low debt
    growing dividends
    growing book value
    hidden value represented in spending in research spending
    buy and keep
    almost similar to J&J
  • T
    Why SENS NOW? This is very important statement from Founder and CEO of FibroGEN INC. A company 3 times bigger then Sense with MC of 5 billion dollars.

    “ I have to say I have been a long time believer in this Company and have been dumbfounded on why it has taken till now to finally be realized for its value. I am a Biomedical Scientist who helped to found FibroGen, Inc and I feel SENS has more to offer in the long run. Very important technology and an enormous market that needs this type of continuous monitoring. I was a speaker at a Juvenile Diabetes Medical Meeting in Dallas Tx in 1981 and the physicians were praying for something like the SENS technology to help Diabetics become healthier and safer. Now it is here and with future work to couple the sensors with a pump to deliver the correct amount of insulin you will have the dream that has been the Holy Grail for Diabetic Therapy for 45 years. I am happy to have found such a great company and I think they should go to $100 and beyond.
  • C
    Down 4.5% today. Any reason down so much compared to rest of market?
  • T
    Dear MDT comrades. Let's use our common sense and invest in SENS. SENS is revolutionary internal CGM that will bring Freedom and Independence to your diabetics. Invest in the Company that will change the Healthcare for diabetic population and invest in SENS. Eversense XL CGM 180 day model will be FDA approved very soon. Dexcom and Abbott external CGMS will become obsolete in a few years. Please invest in Senseonic before it is too late. It is only INTERNAL CGM sensor in the world. Dexcom and Abbott CGM cannot compete. Future of Eversense CGM is here now. Join SENS before It's too late. Come on compatriots lets invest in REAL GROWTH stock of the future...SENS
  • B
    Bill mddb
    ...Yes, I was referring to US tax based, same sector investment alternatives like Stryker, Edwards, J&J, and so on. The key is that US corporations are taxed on global income less deductions for foreign tax paid. But the US can only tax foreign corporations on US revenues. To try and do otherwise would result in quick retaliation. MDT has been running around a 15% - 16% blended overall tax rate with the base US rate at 21% covering 53% of MDT's revenues. Taxes are complicated for multinationals but the back of an envelope shows MDT with a current positive gap of 5% - 5.5%. If the US corporate rate goes from 21% to 28% or up 7% it would raise MDT's overall blended rate by about 3.5% to 18.5% - 19% compared to 28%. The positive gap would then be 9% - 9.5% from the new base rate of 28%, up from the current 5% - 5.5% positive gap. This is why the inversion looks so good at this point. Because if rates do go up to 28% the positive gap for MDT will approach a dime on a dollar of global taxable income and that is a lot of cash flow that MDT will be able to reinvest in the business or payout to shareholders. Omar was a True Believer in the inversion and pushed it through in the face of direct opposition from President Obama resulting in the Treasury Sect. Jack Lew changing the rules for corporations trying to invert, for the sole purpose of stopping MDT from switching to Ireland. Omar was right.
  • J
    $ASYS conversation
    The robotic surgery market includes
    $MDT market cap 158B
    $ISRG market cap 94B
    $SYK market cap 91B
    $ZBH market cap 34B
    A lesser known play that uses high frequency ultrasound to target cancer without the incision is EDAP if you want to broaden the portfolio. The robotics guides the waves and essentially burns the cancer cells killing them and the body takes care of the rest.
  • K
    let's go
  • B
    Bill mddb
    As I think about the value of my investments considering a hike of corporate taxes, the 2015 inversion comes to mind. About 53% of MDT revenue comes from the US. The bulk of employee comp and R&D is in the US. I haven't seen a breakdown of MDT's taxable income in the 160 or so countries it sells to. The inversion is looking good in the rear view mirror as a new tax plan seems high on the new priority list in DC.
  • B
    Bill mddb
    With fundamentals intact, MedTech to outperform in 2021 as vaccines drive recovery
    Dec. 26, 2020 11:12 PM ETMedtronic plc (MDT)By: Dulan Lokuwithana, SA News Editor1 Comment
    Reversing the contraction this year, MedTech could outperform in 2021, J.P. Morgan Securities predict, citing the sector’s potential to combine the ‘strong vaccine-driven recovery trade’ with ‘positive underlying sector fundamentals.’ Despite a less bullish timeline for recovery, the analysts from SVB Leerink shared a similar view adding that the pandemic-driven in telehealth could benefit ‘all medtech subsectors.’
    According to JPM forecasts, in 2021, the industry top-line and bottom-line will expand at 10.1% and 24.8% YoY, compared to an estimated decline of 0.5% and 12.7% YoY in 2020, respectively.
    The analysts at JPM led by Robbie Marcus term the upcoming year as ‘a tale of two cities,’: a strong back half, benefited from the vaccine rollout, easy comps, and the deferred procedures, contrasting the first half likely impacted from the pandemic headwinds amid the ongoing surge in cases and another post-holiday COVID-19 wave.
    Despite the near-term uncertainty, they view the ‘underlying fundamentals of MedTech as healthy,’ with ‘meaningful innovation and undertreated end-markets’ supporting ‘a return to normalized growth in the mid-single digits’ in the future.
    The report from JPM name Medtronic (NYSE:MDT) and Dexcom (NASDAQ:DXCM) as top large-cap picks and Insulet (NASDAQ:PODD) and AtriCure (NASDAQ:ATRC) as top small-cap picks.
    For Medtronic, the proven track record of execution, reinforced by the new management and improving fundamentals, should ‘shine-through’ in a post-pandemic scenario, the analysts point out, expecting the company, with a valuation gap to peers, to outperform the broader group with multiple expansion along the way.
    With pharmacy channel headwinds behind, Dexcom is ‘well-positioned ahead of a G7 launch’ as the company focuses on deeper penetration and new market opportunities to ensure long-term success, the report suggests.
    Having demonstrated resilience amid pandemic headwinds, both Insulet and AtriCure have a 'long runway for growth,’ the researchers write, citing their upcoming product launches.
  • J
    It's 1/15/21 and I haven't received my quarterly dividend...anyone else having the same issue?
  • D
    Cramer interviewing CEO of MDT tonight on CNBC
  • b
    Medtronic was upgraded by Goldman Sachs today to overweight, with a $140 price target.
  • B
    Bill mddb
    A dearth of sellers today. It will take a while, maybe a year from now when revenue has been growing up from the baseline $28 - $29 bil, MDT should be back in the market buying back shares. There should be new funds getting into MDT given the revenue recovery and super news about products and therapies being announced. Working remotely from home probably suites many bio-med engineers and the projects as well. Morgan Stanley may be right about their $140 target for 12/21.
  • T
    💰💰💰💰 TRXC IS A QUADRUPLE PLAY and Others will just steadily increase